775 related articles for article (PubMed ID: 19464821)
1. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
2. Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy.
Mantini G; Tagliaferri L; Mattiucci GC; Balducci M; Frascino V; Dinapoli N; Di Gesù C; Ippolito E; Morganti AG; Cellini N
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e721-6. PubMed ID: 21277100
[TBL] [Abstract][Full Text] [Related]
3. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
4. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma.
Aizer AA; Yu JB; Colberg JW; McKeon AM; Decker RH; Peschel RE
Radiother Oncol; 2009 Nov; 93(2):185-91. PubMed ID: 19800702
[TBL] [Abstract][Full Text] [Related]
5. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
7. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
8. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
[TBL] [Abstract][Full Text] [Related]
9. Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?
Bittner N; Merrick GS; Wallner KE; Butler WM; Galbreath R; Adamovich E
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1078-84. PubMed ID: 19553031
[TBL] [Abstract][Full Text] [Related]
10. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
[TBL] [Abstract][Full Text] [Related]
11. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.
Jereczek-Fossa BA; Zerini D; Vavassori A; Fodor C; Santoro L; Minissale A; Cambria R; Cattani F; Garibaldi C; Serafini F; Matei VD; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):115-25. PubMed ID: 19004572
[TBL] [Abstract][Full Text] [Related]
12. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement.
Jacob R; Hanlon AL; Horwitz EM; Movsas B; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):695-701. PubMed ID: 15708247
[TBL] [Abstract][Full Text] [Related]
13. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
[TBL] [Abstract][Full Text] [Related]
14. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy.
Macdonald OK; Schild SE; Vora SA; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
J Urol; 2003 Nov; 170(5):1833-7. PubMed ID: 14532786
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.
Palma D; Tyldesley S; Blood P; Liu M; Morris J; Pickles T;
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1425-9. PubMed ID: 17394943
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
19. Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer.
Vesprini D; Catton C; Jacks L; Lockwood G; Rosewall T; Bayley A; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Nichol A; Skala M; Warde P; Bristow RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):608-16. PubMed ID: 22099034
[TBL] [Abstract][Full Text] [Related]
20. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
